BiotechTube

Ibuprofen + Diclofenac + Methyl-salicylate / Menthol + Placebo

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 19/100
19
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pain

Conditions

Pain

Trial Timeline

Mar 1, 2015 → May 1, 2015

NCT ID
NCT02666846

About Ibuprofen + Diclofenac + Methyl-salicylate / Menthol + Placebo

Ibuprofen + Diclofenac + Methyl-salicylate / Menthol + Placebo is a phase 1 stage product being developed by Futura Medical for Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT02666846. Target conditions include Pain.

What happened to similar drugs?

20 of 20 similar drugs in Pain were approved

Approved (20) Terminated (4) Active (0)
✅Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
✅0.75% bupivacaine + .75% bupivacaine + .75% bupivacaineSI-BONEApproved
✅pregabalin sustained release tablet + pregabalin immediate release capsuleYuhanApproved
✅Topical High dose Capsaicin + Topical PlaceboAstellas PharmaApproved
✅Solifenacin succinate treatment + Oxycodone and acetaminophen combination treatmentAstellas PharmaApproved
✅Qutenza + PregabalinAstellas PharmaApproved
✅Duloxetine + Pregabalin + PlaceboShionogiApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02666846Phase 1Completed

Competing Products

20 competing products in Pain

See all competitors
ProductCompanyStageHype Score
DFN-15 (Celecoxib Oral Solution) 62.5 mg + DFN-15 (Celecoxib Oral Solution) 125 mg + DFN-15 (Celecoxib Oral Solution) 250 mg + PlaceboDr. Reddy's LaboratoriesPhase 2
32
PRF110- oily solution (Ropivacaine)PainReformPhase 2
25
PRF110PainReformPhase 2
21
PRF-108 + Placebo + Ropivacaine + PRF-110PainReformPhase 1/2
22
TRV130 1.5 mg + TRV130 3 mg + TRV130 4.5 mg + Morphine 10 mg + PlaceboTrevenaPhase 1
19
Oliceridine + Placebo + MorphineTrevenaPhase 3
30
Oliceridine + Placebo + MorphineTrevenaPhase 3
30
TRV130TrevenaPhase 3
30
TRV130 + Morphine + PlaceboTrevenaPhase 2
25
TRV130TrevenaPhase 2
17
LY3556050 + PlaceboEli LillyPhase 2
35
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
44
Nanoformed Piroxicam IR Tablet + Felden (piroxicam) Tablets + Brexidol (piroxicam) TabletsNanoform FinlandPhase 1
23
0.75% bupivacaine + .75% bupivacaine + .75% bupivacaineSI-BONEApproved
29
LY3526318 + PlaceboEli LillyPhase 2
35
LY3857210 + PlaceboEli LillyPhase 2
35
OK-101 0.05% + OK-101 0.1% + PlaceboOKYO PharmaPhase 2
17
YHD1119 + LyricaYuhanPhase 1
29
YHD1119 + LyricaYuhanPhase 1
29
YHD1119 + LyricaYuhanPhase 3
40